Drug Profile

Clazosentan - Idorsia Pharmaceuticals

Alternative Names: ACT-108475; AXV 034; AXV 034343; Clazosentan sodium; PIVLAZ; RO-61-1790; VML-588

Latest Information Update: 18 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Roche
Developer Idorsia Pharmaceuticals
Class Antispasmodics; Dioxanes; Neuroprotectants; Phenyl ethers; Pyridines; Pyrimidines; Small molecules; Sulfonamides; Tetrazoles
Mechanism of Action Endothelin A receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Cerebral vasospasm
New Molecular Entity Yes

Highest Development Phases

Marketed Cerebral vasospasm

Most Recent Events

15 Apr 2024 Clazosentan licensed to Handok in South Korea
31 Mar 2024 Sosei Heptares is now called Nxera Pharma
07 Dec 2023 Registered for Cerebral vasospasm in South Korea (IV)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com